TauRx Hosts Event to Inform on bvFTD Trial at International Conference on Frontotemporal Dementias

TauRx Hosts Event to Inform on bvFTD Trial at International Conference on Frontotemporal Dementias

TauRx-Therapeutics-Initiates-Two-Phase-III-Trials-For-Alzheimers-DrugTauRx Therapeutics Ltd, a spin-off company from the University of Aberdeen in Scotland, recently hosted a breakfast event to inform both patients and caregivers about their phase III clinical trial, which will test a treatment for behavioral variant Frontotemporal Dementia (bvFTD), and is currently enrolling participants. The "Meet the Experts" breakfast was held on Friday, October 24, which included a Caregivers Session, during the 9th International Conference on Frontotemporal Dementias (ICFTD), at the Sheraton Vancouver Wall Centre, Canada.

During the breakfast event the Chairman of TauRx, Claude Wischik, a board-certified psychiatrist and professor of Old Age Psychiatry at the University of Aberdeen, and Sharon Cohen, the director of the Toronto Memory Program, a multidisciplinary and community-based medical facility, specialized in the diagnosis and treatment of dementia and responsible for one of the largest clinical trials in Canada, hosted a presentation on the disease, which is the second most common type of dementia, and for which there is no  approved treatment.

"Because bvFTD i

Subscribe or to access all post and page content.